Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

Progression‐free survival ‐ not reported · recurrent platinum‐resistant EOC

The review found no eligible studies for this question.

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dexrazoxane vs no cardioprotective intervention or placebo

Progression‐free survival · adults with cancer receiving anthracyclines

Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 0.62 [0.43, 0.9]
1 study · 164 participants
Low